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Abstract
Background:  Carcinoma of urinary bladder is one of the leading causes of death in India.
Successful treatment of bladder cancer depends on the early detection & specific diagnostic
approaches. In the present study, microsatellite instability (MSI) has been evaluated as a prognostic
marker in patients with superficial urinary bladder cancer in lower urinary tract for determining
risk of recurrence.
Methods: A total of 44 patients with bladder tumors diagnosed with Transitional Cell Carcinomas
[TCC] from lower urinary tract were selected for the study. Tumors were staged and graded
according to AJCC-UICC (1997) classification and patients were followed with cystoscopy as per
the protocol. Polymerase chain reaction (PCR) was done to amplify microsatellite sequences at
mononucleotide BAT – 26, BAT – 40, TGFβ RII, IGFIIR, hMSH3, BAX and dinucleotide D2S123,
D9S283, D9S1851 and D18S58 loci in blood (control) and tumor DNA. PCR products were
separated on 8% denaturing polyacrylamide gel and visualized by autoradiography.
Results: MSI was observed in 72.7% of tumors at BAT – 26, BAT – 40, D2S123, D9S283, D9S1851
and D18S58 loci. Good association of MSI was seen with tumor stage and grade. MSI – High
(instability at > 30% of loci) was frequently observed in high stage (40.6%) and high grade (59.4%)
tumors. Of 24 tumors of Ta-T1 stage with different grades, 11 (9/18 high grade and 2/6 low grade
tumors) recurred in the mean duration of 36 months. MSI positivity was significantly high in patients
who had one or more recurrences (p = 0.02 for high grade and 0.04 for low grade tumors).
Conclusions: MSI may be an independent prognostic marker for assessing risk of recurrence in
superficial tumors irrespective of the grade. Further studies on progression would help in stratifying
the patients of T1G3 for early cystectomy vs bladder preservation protocol.
Background
Amongst the genitourinary cancer, carcinoma of the uri-
nary bladder is one of the leading causes of death in
Indian population. Transitional cell carcinoma (TCC) is
the commonest histopathological variant where stage and
grade are the two important prognostic factors to know
the clinical behavior of these tumors. Superficial tumors
with different grades behave differently e.g. tumors with
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high grade recur early and progress to invasive bladder
cancer very soon. This behavior of same stage of the tumor
but with varied grades is attributed to genetic alterations.
Bladder cancer manifesting from superficial to aggressive
muscle invasive tumors undergoes a sequence of genetic
alterations. Primary chromosomal aberrations are associ-
ated with tumor development while secondary chromo-
somal abnormalities lead to progression to a more
advanced stage. A frequent loss of heterozygosity (LOH)
on chromosomes 4, 5, 8, 9, 11 and 17 is considered a
major event in the carcinogenesis of bladder cancer [1,2].
Defects in mismatch repair (MMR) genes result in replica-
tion errors and genetic instability. Faulty mismatch repair,
generally observed as somatic variation in size of micros-
atellites (short tandem repeat sequences in genome) is
referred as microsatellite instability (MSI) [3]. MSI and
LOH in bladder cancer have been reported by several
investigators [4,5].
A successful treatment of bladder cancer depends on early
detection and more specific diagnostic approaches. Prene-
oplastic changes of the bladder epithelium or superficial
tumors as an early event precede invasive bladder carcino-
mas. Though the higher grade and stage portends a worst
prognosis, superficial tumors of same stage and grade
have different outcome in different patients. Due to lim-
ited utility of these prognosticators in patients with super-
ficial bladder tumor, there is a need to analyze new
molecular parameters in predicting the prognosis and risk
of recurrence. The following study is based on MSI analy-
sis in tumor tissues to evaluate its utility as a marker for
early detection of recurrent bladder carcinomas from
lower urinary tract and thus help in deciding treatment
modalities.
Methods
Patient selection
Total of 44 patients with male & female ratio of (42:2) of
TCC with a mean age of 62 years were included for the
study after the approval from ethical committee. All the
patients selected for the study were not having any famil-
ial cancer syndrome or had previous history of cancer to
the best of our knowledge.
All the tumors were resected transurethrally from the
lower urinary tract. Part of superficial tissue specimen
obtained after transurethral resection of bladder tumor
(TURBT) was collected immediately in liquid nitrogen.
Matched control sample (5 ml of peripheral blood) from
all patients was collected in 200 µl of 0.5 M EDTA. The
tumor stage and grade was assigned according to the TNM
classification by American Joint Committee on Cancer
(AJCC-UICC, 1997) [6]. Tumors of superficial nature clas-
sified as T1 or Ta while with deep muscular invasion were
assigned as T2 or T3. Similarly tumor grading was done as
G1 (low grade) and G2 or G3 (high grade). Patients were
followed for recurrence (the number of times patient
develops the tumor) every three months for 36 months
with cytology and cystoscopy. The clinical and pathologi-
cal characteristics of all the patients are summarized in
Table 1.
DNA isolation
Superficial tumor tissue specimens of histologically con-
firmed bladder tumors and peripheral blood (frozen) of
the same patient were processed for DNA isolation using
phenol-chloroform extraction method [7].
MSI analysis
Table 2 demonstrates the characteristic features of the
microsatellite markers evaluated in the present study. The
primer sequences for mono and dinucleotide microsatel-
lite markers were searched from human genomic data-
base. Polymerase chain reaction (PCR) amplification of
DNA was done using primers of concentration of 6 pmol,
200 µM dNTPs, 10 mM Tris – Cl (pH 8.3), 50 mM KCl, 1.5
mM MgCl2, 0.25 units of Taq polymerase (MSI, Fermen-
tas), 100 ng DNA and 2 µCi [α-32P] dCTP (specific activ-
ity: 4000 Ci/mM) (BRIT, India) in a volume of 25 µl. PCR
conditions involved an initial denaturation at 95°C for 3
min followed by 30 cycles (95°C for 1 min, 50°C to 60°C
for 2 min and 72°C for 3 min) and a final extension at
72°C for 8 min. PCR products were mixed with equal vol-
ume of formamide loading dye (95% formamide, 20 mM
EDTA, 0.05% bromophenol blue, 0.05% Xylene cyanol),
denatured for 5 min at 95°C and loaded onto 8%
polyacrylamide gel containing 7 M urea. Gels were run at
55 W for 2 hours, transferred onto a Whatman sheet fol-
lowed by an exposure to X-ray film (Kodak) for desired
time and then developed.
The tumor was designated unstable if its PCR product had
altered band pattern when compared to alleles in corre-
sponding matched blood DNA [8]. Out of he motifs stud-
ied, BAT-26 & BAT-40, the mononucleotide poly A
repetitive loci have been shown to exhibit polymorphism
[9]. The change either borderline or major deletions/
insertions at this loci is compared in tumor tissue of the
same patient with the normal tissue in colorectal tumors
[8]. Tumors were called MSI-High (MSI-H) when they
showed instability at > 30% of loci and MSI-Low (MSI-L)
if they showed at or less than 30% of loci.
Statistical analysis
Statistical tests, including, 2 × 2 contingency table, Fisher's
exact probability test (one or two tailed), Karl Pearson's
correlation test were applied to assess the relation
between the microsatellite instability in tumors and clin-BMC Urology 2005, 5:2 http://www.biomedcentral.com/1471-2490/5/2
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icopathological parameters. A student t test was applied to
compare the number of genomic alterations between
tumors of different grades and stages.
Results
A panel of ten microsatellite markers situated on chromo-
somes 2, 3, 5, 6, 9, 18 and 19 were screened to look for
microsatellite instability in superficial tumor tissues and
compared with blood DNA. Alterations were detected in
32 of 44 patients (72.7%).
Out of the six mononucleotide microsatellite markers
analyzed, only BAT – 26 and BAT – 40 in 17.7% and
24.4% of the cases could demonstrate changes respec-
tively while TGFβ RII, IGFIIR, hMSH3 and BAX were mic-
rosatellite stable (MSS). BAT-26 & BAT-40 exhibited
Table 1: Clinical and pathological features of the patients diagnosed with bladder Carcinoma
Case no. @Age/ $Gender Stage Grade #Recurrence MSI
BC 1 45/M T2 High, G3 2 *High (BAT – 26, BAT – 40)
BC 2 59/M T1 High, G2 1 High (BAT – 26, BAT – 40, D9S1851)
BC 3 66/M Ta Low, G1 0 High (D9S283, D9S1851)
BC 4 39/M T2 High, G3 0 High (BAT – 26, BAT – 40, D9S283)
BC 5 72/M T2 High, G3 0 High (BAT – 40, D9S1851)
BC 6 59/M T2 High, G2 1 Low (D9S1851)
BC 7 78/M T2 High, G3 0 High (D9S283, D9S1851)
BC 8 52/M Ta High, G2 0 High (BAT – 40, D9S283, D9S1851)
BC 9 71/M Ta High, G2 0 **Low (BAT – 40)
BC 10 84/M T1 High, G2 0 ***MSS
BC 11 55/M T1 High, G1 0 MSS
BC 12 53/M T2 High, G2 0 Low (D18S58)
BC 13 52/M T3 High, G3 0 High (D9S283, D9S1851)
BC 14 40/M T3 High, G3 0 MSS
BC 15 55/M T2 High, G3 0 MSS
BC 16 60/M T2 High, G3 0 High (BAT – 40, D9S283, D18S58)
BC 17 66/M T1 High, G3 1 High (BAT – 40, D2S123, D9S283, D9S1851, D18S58)
BC 18 80/M T1 High, G3 1 High (BAT – 26, D9S283, D18S58)
BC 19 42/M T1 High, G2 0 Low (D9S283)
BC 20 73/M T3a High, G3 0 MSS
BC 21 55/M T2 High, G3 0 Low (D2S123)
BC 22 58/M T2 High, G3 0 High (BAT – 26, D2S123)
BC 23 70/M T1 High, G2 0 Low (BAT – 26)
BC 24 53/M Ta High, G3 0 High (D9S1851, D18S58)
BC 25 60/M T2 High, G3 0 High (D9S283, D9S1851)
BC 26 54/M Ta Low, G1 0 MSS
BC 27 72/M Ta High, G2 0 MSS
BC 28 58/M T1 High, G3 0 Low (D9S283)
BC 29 80/M T2 High, G3 0 High (D9S283, D9S1851)
BC 30 64/M Ta High, G2 2 Low (BAT – 40)
BC 31 74/M Ta High, G3 0 High (D9S283, D9S1851)
BC 32 60/M T1 Low, G1 0 MSS
BC 33 41/M T1 Low, G1 3 Low (BAT – 26)
BC 34 66/ F T2 High, G3 0 High (D2S123, D9S283)
BC 35 53/M T1 Low, G1 0 Low (D2S123)
BC 36 66/M T1 High, G2 1 High (D2S123, D9S283, D18S58)
BC 37 55/M T2 High, G3 0 High (BAT – 26, BAT – 40, D9S1851)
BC 38 65/M T2 High, G3 0 Low (D18S58)
BC 39 69/M T1 Low, G1 0 Low (D9S283)
BC 40 74/M T1 High, G2 1 MSS
BC 41 72/ F T2 Low, G1 0 MSS
BC 42 71/M T1 High, G3 1 Low (D9S283)
BC 43 64/M T2 High, G3 0 High (BAT – 40, D9S1851)
BC 44 73/M T1 High, G2 1 Low (D9S283)
@Age = (years); $Gender = (M: Male/F: Female); *MSI – H = MSI – High; **MSI – L = MSI – Low; ***MSS = microsatellite stable
# Recurrence (0, 1, 2, 3) = Number of times the tumor recurredBMC Urology 2005, 5:2 http://www.biomedcentral.com/1471-2490/5/2
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borderline changes in tumor DNA as compared to control
DNA. We also sequenced the tumor & normal PCR prod-
uct for these microsatellites to prove the change. The dinu-
cleotide markers- D2S123, D9S283, D9S1851 and
D18S58 exhibited altered electrophoretic migration pat-
tern in 15.5%, 40%, 31.1% and 17.8% bladder tumors
respectively. The most frequent microsatellite alteration
was detected on the markers of chromosome 9 (D9S283
followed by D9S1851) (Fig 1 and 2).
A significant association of MSI – H with T2 or T3 stage
tumors (2 × 2 contingency table, p = 0.05) and ≥ G2 grade
tumors (Fisher's exact probability test, two tailed, p =
0.08) was observed (Table 1).
Total genomic alterations were analyzed among different
stages and grades. Changes were comparable among (24/
44) T1-Ta and (20/44) T2-T3 tumors that included 35 (13
insertions, 6 deletions, 10 LOH and 6 BA) and 31 (10
insertions, 8 deletions & LOH and 5 BA) respectively (p >
Table 2: Characteristic features of microsatellite markers examined in urinary bladder tumors
Microsatellite marker Repeat pattern Chromosomal location ~ PCR product size
BAT 26 (A)26 5th intron of hMSH2, 2p 117 – 130 bp
BAT 40 (A)40 2ndintron of β hydroxy steroid dehydrogenase 94 – 112 bp
BAX (38 – 41) (G)8 19q13.3 – q13.4 94 bp
TGFβ RII (665 – 737) (A)10 3p22 73 bp
IGFIIR (4030 – 4140) (G)8 6q26 – 27 110 bp
HMSH3 (381 – 383) (A)8 5q 150 bp
D2S123 (CA)13TA 2p16 197 – 227 bp
(CA)15(T/GA)7
D9S283 (CA)n 9q13 – q22 178 – 203 bp
D9S1851 (CA)n 9q22.3 143 – 159 bp
D18S58 (GC)5GA(CA)17 18q22.3 144 – 160 bp
Changes in allelic pattern indicated by an arrow, observed in superficial tissue (Ts) as compared to blood (germline DNA, N) of  patients with bladder carcinoma Figure 1
Changes in allelic pattern indicated by an arrow, observed in superficial tissue (Ts) as compared to blood (germline DNA, N) of 
patients with bladder carcinoma: (A) Deletion at BAT – 26; (B) Insertion at BAT – 40; (C) Insertion at D2S123; (D) Loss of het-
erozygosity at D9S283; (E) Biallelic alteration at D9S1851 and (F) Deletion at D18S58
BAT – 26
(A)
12
N   Ts
BAT – 40
(B)
1        2
N      Ts
D2S123
(C)
1     2  
N     Ts 
D9S283
(D)
1    2   
N  Ts 
1          2
N        Ts
D9S1851
(E)
D18S58
(F)
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N     TsBMC Urology 2005, 5:2 http://www.biomedcentral.com/1471-2490/5/2
Page 5 of 7
(page number not for citation purposes)
0.05). High grade (G2-G3) (37/44) carcinomas encom-
passed 63 alterations (24 insertions, 14 deletions, 15 LOH
and 10 BA) and low grade (G1) (7/44) bladder tumors
had only 5 (1 each deletion & BA and 3 LOH) (p = 0.01)
Recurrence of tumors (mean duration of 36 months) was
correlated with MSI in 24 superficial (Ta-T1) tumors in
patients who turned up for regular follow up (Table 1).
This group comprised 18 high grade and six low grade
tumors. In the high grade tumors, 13 were MSI+, and 8 of
them (61.5%). showed recurrence while only one (1/5,
20%) MSI- recurred. Amongst low grade tumors (6), 2
recurrences were noted only in MSI+ group and none of
the MSI- showed recurrence (Fisher's exact probability
two tailed test) (p = 0.02 for high grade tumors) and (p =
0.04 for low grade tumors).
Discussion
This present work is a continuation of the previous pub-
lished work where thirty bladder tumors were analyzed
for the presence of MSI at BAT-26, BAT-40, TGFβ RII,
IGFIIR, hMSH3 and BAX. The initial results encouraged
examining the role of MSI/ LOH in more number of
tumors with expanded panel of markers [7]. In this paper,
44 patients of bladder cancer are examined for MSI at
BAT-26, BAT-40, TGFbRII, IGFIIR, BAX, & hMSH3 &
D2S123, D9S283, D9S1851 & D18S58 dinucleotide
repeat motifs. The MSI results are further analysed with
clinicopathological features: stage and grade of the tumors
& its recurrence in due course of time. The importance of
MSI in the diagnosis of recurrence in superficial cases
irrespective of grade & thus advocate the bladder cystec-
tomy as a treatment modality in these cases.
Genomic instability measured by changes in tumor tissues
as compared to blood of the same patient at repetitive loci
was detected in 72.7% cases of bladder carcinoma. It dif-
fers from previous observation, which shows infrequent
occurrence of MSI in TCC using different microsatellite
markers [10]. However, low frequency of MSI with altera-
tions of dinucleotide repeats in TCC of the urinary tract
was found as 21% and 16.6% in two independent studies
[11,12]. MSI and allelic loss in a series of 26 upper urinary
tract tumors using 5 informative microsatellite markers
were examined & this study supports the presence of MSI
in upper urinary tract which is rare event in bladder cancer
[13]. Another study describes MSI and loss of respective
MMR protein by immunostaining in a patient with a
urothelial carcinoma of the ureter and a strongly positive
history of cancer, who was subsequently found to have
HNPCC [14].
In the present study a significant association of MSI with
tumor stage and grade in sporadic bladder tumors sug-
gested MSI as an early event in tumorigenesis. These
results confirm the previous finding where MSI examined
in TCC of bladder with low stage and grade using few mic-
rosatellite markers mostly confined to chromosome 9
[15]. Another study reports 100% tumor instability as
determined by dinucleotide repeat analysis in 14 cases of
Superficial tumor tissues and blood (control) of bladder tumor patients demonstrated no change at (A) TGFβ RII; (B) BAX; (C)  hMSH3 and (D) IGFIIR Figure 2
Superficial tumor tissues and blood (control) of bladder tumor patients demonstrated no change at (A) TGFβ RII; (B) BAX; (C) 
hMSH3 and (D) IGFIIR
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urinary bladder of different stages and grades [16]. Many
studies show relatively high proportion of tumors with
mutations in di, tri, and tetra nucleotide repeat motifs,
although each tumor exhibits only few such mutations
[4]. Recently, a novel form of MSI, termed as EMAST (ele-
vated microsatellite instability at selected tetranucleotide
repeats) has been found to be significantly associated with
mutations in p53 among the bladder cancer tumors, but
no indication of elevated EMAST in tumors with abnor-
mal p53 staining without mutation. EMAST likely reflects
a particular pattern of somatic events that are interactive
with p53 mutation, particularly common in skin cancer
and limited to non-invasive disease in bladder cancer
[17]. The difference between these studies and ours may
be attributed to the number and identity of microsatellite
motifs studied.
Despite clear-cut prognostic differences, genetic altera-
tions were comparable in superficial (Ta-T1) and invasive
bladder carcinomas (T2-T3) suggesting the role of MSI in
progression of bladder cancer as well. However, strong
association of MSI – H with T2-T3 and G2-G3 was
observed. MSI at ≥ 30% of loci has been found in 59.4%
(19/32) of TCC bladder, which is not in accordance with
reported earlier [11,12]. A good association of MSI – H
with high grade superficial tumors may help in deciding
radical surgery to begin with.
Bladder cancer presents as superficial tumor in 75% of the
patients, which can easily be removed by transurethral
resection (TUR). Around 60–80 % of these treated
patients develop recurrence in due course of time. Out of
them, 15% progress to higher grade and stage. With so
much potential for recurrence, patients need to be fol-
lowed up with cystoscopy at regular intervals. Although
many new tumor markers have been proposed but all
have limitations with respect to execution and interpreta-
tion in predicting the recurrence of bladder tumors [18].
Among the molecular markers, alterations in p53, p21WAF/
C1P1, Rb, c-erb B-2 are reported to be associated with
tumor recurrence and progression but little is known to
address MSI [19]. MSI analysis gives higher sensitivity and
easy to execute among other molecular markers, thus
making it a valuable marker for detection of recurrence.
To the best of our knowledge, this is the first study report-
ing MSI as a good prognostic marker that correlates with
risk of recurrence in superficial (Ta-T1) tumors irrespec-
tive of the grade. This may help in deciding radical treat-
ment at an early stage. We could not study the genetic
changes during the progression of tumor, which means
the extension of superficial tumor confined to the mucosa
and submucosa to deep musculature of the bladder. Lim-
itation of this study is a small number of patients but ini-
tial trends show a strong correlation of MSI with
recurrence irrespective of the grade of the tumor. Further
multicentre trial is needed to prove this concept.
Conclusions
MSI has been observed to play important role in evolu-
tion, initiation and progression in bladder tumors.
Patients with high grade superficial disease are reported to
have higher incidence of MSI. Also high frequency of MSI
in superficial tumors showing recurrence irrespective of
grade may provide an indication for more radical
approach to improve the survival.
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